Ervogastat | DGAT2 inhibitor

CAS:
 2186700-33-2
Catalog Number:
 10-4459
Ervogastat chemical structure

Available Options

Size:PriceQuantity 
5 mg$100.00
25 mg$395.00
Request Quote / Bulk / Custom Size
Product Inquiry

Ervogastat (2186700-33-2) is a potent (IC50 = 17.2 nM) and selective (against DGAT1 and MGATs 1-3) inhibitor of diacylglycerol transferase 2 (DGAT2). It reduced liver and plasma triglyceride levels in Sprague-Dawley rats feed a high fat high cholesterol diet by 49% and 70% respectively.1 Ervogastat displayed efficacy in combination with the ACC inhibitor clesacostat in resolving metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.2

References/Citations:

  1. Futatsugi et al. (2022), Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis; J. Med. Chem. 65 15000
  2. Wong et al. (2025), Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomized, double-blind, double-dummy study; Lancet Gastroenterol. Hepatol. 10 924
2186700-33-2, DGAT2 inhibitor, Ergvogastat supplier, Ervogastat, PF-06865571, PF-06865571 supplier, selective DGAT2 inhibitor
CAS:
2186700-33-2
Catalog Number:
10-4459
Activity:
DGAT2 inhibitor
Chemical Names:
2-[5-[(3-Ethoxy-2-pyridinyl)oxy]-3-pyridinyl]-N-[(3S)-oxolan-3-yl]pyrimidine-5-carboxamide
Alternate Name:
PF-06865571
Molecular Weight:
407.43
Molecular Formula:

C21H21N5O4

Solubility:
Soluble in DMSO (>25 mg/ml)
Physical Properties:
Off-white to pale yellow solid
Purity:

>98% HPLC
NMR: (Conforms)

Storage Temperature:
-20°C
Stability:
Stable for up to 2 years when stored as supplied @ -20°C. Solutions in DMSO may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Ervogastat (2186700-33-2) is a potent (IC50 = 17.2 nM) and selective (against DGAT1 and MGATs 1-3) inhibitor of diacylglycerol transferase 2 (DGAT2). It reduced liver and plasma triglyceride levels in Sprague-Dawley rats feed a high fat high cholesterol diet by 49% and 70% respectively.1 Ervogastat displayed efficacy in combination with the ACC inhibitor clesacostat in resolving metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.2

References/Citations:

  1. Futatsugi et al. (2022), Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis; J. Med. Chem. 65 15000
  2. Wong et al. (2025), Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomized, double-blind, double-dummy study; Lancet Gastroenterol. Hepatol. 10 924

STEM CELL

BOGO